Skip to main content
Erschienen in: Neurological Sciences 1/2017

01.05.2017 | SYMPOSIUM - NUTRACEUTICS AND HEADACHE

Usefulness of nutraceuticals in migraine prophylaxis

verfasst von: Florindo D’Onofrio, Simona Raimo, Daniele Spitaleri, Gerardo Casucci, Gennaro Bussone

Erschienen in: Neurological Sciences | Sonderheft 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Several studies have supported the efficacy of complementary and alternative medicine approaches (physical, behavioral and nutraceutical therapies) in the treatment of headache disorders. Nutraceutical treatment consists of taking vitamins, supplements (magnesium, riboflavin, coenzyme Q10, and alpha lipoic acid) and herbal preparations (feverfew and butterbur), and its usage is frequently determined by dissatisfaction with conventional medical therapies. There is a growing body of research on nutraceutical use for migraine prophylaxis. This brief overview provides information about the potential efficacy and side effects of various nutraceutical products summarizing randomized controlled trials of some of the most commonly used non-pharmacological treatments for the prophylaxis and treatment of migraine, including magnesium, coenzyme Q10, riboflavin (vitamin B2), petasites, and feverfew.
Literatur
1.
Zurück zum Zitat Kalra EK (2003) Nutraceutical—definition and introduction. AAPS Pharm Sci 5:27–28CrossRef Kalra EK (2003) Nutraceutical—definition and introduction. AAPS Pharm Sci 5:27–28CrossRef
2.
Zurück zum Zitat Sun-Edelstein C, Mauskop A (2011) Alternative headache treatments: nutraceuticals, behavioral and physical treatments. Headache 51(3):469–483CrossRefPubMed Sun-Edelstein C, Mauskop A (2011) Alternative headache treatments: nutraceuticals, behavioral and physical treatments. Headache 51(3):469–483CrossRefPubMed
3.
Zurück zum Zitat Daniel O, Mauskop A (2016) Nutraceuticals in acute and prophylactic treatment of migraine. Curr Treat Options Neurol 18(4):14CrossRefPubMed Daniel O, Mauskop A (2016) Nutraceuticals in acute and prophylactic treatment of migraine. Curr Treat Options Neurol 18(4):14CrossRefPubMed
4.
Zurück zum Zitat Kandasamy AD (2014) Nutraceuticals for the treatment of migraine prophylaxis. Discov Phytomed 1:16–21CrossRef Kandasamy AD (2014) Nutraceuticals for the treatment of migraine prophylaxis. Discov Phytomed 1:16–21CrossRef
5.
6.
Zurück zum Zitat Rybicka JM, Balce DR, Chaudhuri S, Allan ERO, Yates RM (2012) Phagosomal proteolysis in dendritic cells is modulated by NADPH oxidase in a pH-independent manner. EMBO J 31(4):932–944CrossRefPubMed Rybicka JM, Balce DR, Chaudhuri S, Allan ERO, Yates RM (2012) Phagosomal proteolysis in dendritic cells is modulated by NADPH oxidase in a pH-independent manner. EMBO J 31(4):932–944CrossRefPubMed
7.
Zurück zum Zitat Gaul C, Diener HC, Danesch U; Migravent® Study Group (2015) Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial. J Headache Pain 16:516 Gaul C, Diener HC, Danesch U; Migravent® Study Group (2015) Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial. J Headache Pain 16:516
8.
Zurück zum Zitat Mauskop A, Altura BT, Altura BM (2002) Serum ionized magnesium levels and serum ionized calcium/ionized magnesium ratios in women with menstrual migraine. Headache 42:242–248CrossRefPubMed Mauskop A, Altura BT, Altura BM (2002) Serum ionized magnesium levels and serum ionized calcium/ionized magnesium ratios in women with menstrual migraine. Headache 42:242–248CrossRefPubMed
9.
Zurück zum Zitat Chiu HY, Yeh TH, Huang YC, Chen PY (2016) Effects of intravenous and oral magnesium on reducing migraine: a meta-analysis of randomized controlled trials. Pain Physician 19(1):E97–E112PubMed Chiu HY, Yeh TH, Huang YC, Chen PY (2016) Effects of intravenous and oral magnesium on reducing migraine: a meta-analysis of randomized controlled trials. Pain Physician 19(1):E97–E112PubMed
10.
Zurück zum Zitat Teigen L, Boes CJ (2015) An evidence-based review of oral magnesium supplementation in the preventive treatment of migraine. Cephalalgia 35(10):912–922CrossRefPubMed Teigen L, Boes CJ (2015) An evidence-based review of oral magnesium supplementation in the preventive treatment of migraine. Cephalalgia 35(10):912–922CrossRefPubMed
11.
Zurück zum Zitat Schoenen J, Jacquy J, Lenaerts M (1998) Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 50(2):466–470CrossRefPubMed Schoenen J, Jacquy J, Lenaerts M (1998) Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 50(2):466–470CrossRefPubMed
12.
Zurück zum Zitat Sandor PS, Afra J, Ambrosini A, Schoenen J (2000) Prophylactic treatment of migraine with beta-blockers and riboflavin: differential effects on the intensity dependence of auditory evoked cortical potentials. Headache 40:30–35CrossRefPubMed Sandor PS, Afra J, Ambrosini A, Schoenen J (2000) Prophylactic treatment of migraine with beta-blockers and riboflavin: differential effects on the intensity dependence of auditory evoked cortical potentials. Headache 40:30–35CrossRefPubMed
13.
Zurück zum Zitat Boehnke C, Reuter U, Flach U, Schuh-Hofer S, Einhäupl KM, Arnold G (2004) High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre. Eur J Neurol 11(7):475–477CrossRefPubMed Boehnke C, Reuter U, Flach U, Schuh-Hofer S, Einhäupl KM, Arnold G (2004) High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre. Eur J Neurol 11(7):475–477CrossRefPubMed
14.
Zurück zum Zitat MacLennan SC, Wade FM, Forrest KM, Ratanayake PD, Fagan E, Antony J (2008) High-dose riboflavin for migraine prophylaxis in children: a double-blind, randomized, placebo-controlled trial. J Child Neurol 23(11):1300–1304CrossRefPubMed MacLennan SC, Wade FM, Forrest KM, Ratanayake PD, Fagan E, Antony J (2008) High-dose riboflavin for migraine prophylaxis in children: a double-blind, randomized, placebo-controlled trial. J Child Neurol 23(11):1300–1304CrossRefPubMed
15.
Zurück zum Zitat Grossmann M, Schmidramsl H (2000) An extract of Petasites hybridus is effective in the prophylaxis of migraine. Int J Clin Pharmacol Ther 38(9):430–435CrossRefPubMed Grossmann M, Schmidramsl H (2000) An extract of Petasites hybridus is effective in the prophylaxis of migraine. Int J Clin Pharmacol Ther 38(9):430–435CrossRefPubMed
16.
Zurück zum Zitat Diener HC, Rahlfs VW, Danesch U (2004) The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. Eur Neurol 51(2):89–97CrossRefPubMed Diener HC, Rahlfs VW, Danesch U (2004) The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. Eur Neurol 51(2):89–97CrossRefPubMed
17.
Zurück zum Zitat Lipton RB, Göbel H, Einhäupl KM, Wilks K, Mauskop A (2004) Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology 63(12):2240–2244CrossRefPubMed Lipton RB, Göbel H, Einhäupl KM, Wilks K, Mauskop A (2004) Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology 63(12):2240–2244CrossRefPubMed
18.
Zurück zum Zitat Pothmann R, Danesch U (2005) Migraine prevention in children and adolescents: results of an open study with a special butterbur root extract. Headache 45(3):196–203CrossRefPubMed Pothmann R, Danesch U (2005) Migraine prevention in children and adolescents: results of an open study with a special butterbur root extract. Headache 45(3):196–203CrossRefPubMed
19.
Zurück zum Zitat Utterback G, Zacharias R, Timraz S, Mershman D (2014) Butterbur extract: prophylactic treatment for childhood migraines. Complement Ther Clin Pract 20(1):61–64CrossRefPubMed Utterback G, Zacharias R, Timraz S, Mershman D (2014) Butterbur extract: prophylactic treatment for childhood migraines. Complement Ther Clin Pract 20(1):61–64CrossRefPubMed
20.
Zurück zum Zitat Diener HC, Pfaffenrath V, Schnitker J, Friede M, Henneicke-von Zepelin HH (2005) Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention—a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia 25(11):1031–1041CrossRefPubMed Diener HC, Pfaffenrath V, Schnitker J, Friede M, Henneicke-von Zepelin HH (2005) Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention—a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia 25(11):1031–1041CrossRefPubMed
21.
Zurück zum Zitat Pittler MH, Ernst E (2004) Feverfew for preventing migraine. Cochrane Database Syst Rev 1:CD002286 Pittler MH, Ernst E (2004) Feverfew for preventing migraine. Cochrane Database Syst Rev 1:CD002286
22.
Zurück zum Zitat Sandor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D, Seidel L, Agosti RM, Schoenen J (2005) Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 64(4):713–715CrossRefPubMed Sandor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D, Seidel L, Agosti RM, Schoenen J (2005) Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 64(4):713–715CrossRefPubMed
23.
Zurück zum Zitat Rozen TD, Oshinsky ML, Gebeline CA, Bradley KC, Young WB, Shechter AL, Silberstein SD (2002) Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 22(2):137–141CrossRefPubMed Rozen TD, Oshinsky ML, Gebeline CA, Bradley KC, Young WB, Shechter AL, Silberstein SD (2002) Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 22(2):137–141CrossRefPubMed
24.
Zurück zum Zitat Shoeibi A, Olfati N, Soltani Sabi M, Salehi M, Mali S, Akbari Oryani M (2016) Effectiveness of coenzyme Q10 in prophylactic treatment of migraine headache: an open-label, add-on, controlled trial. Acta Neurol Belg 117:103–109CrossRefPubMed Shoeibi A, Olfati N, Soltani Sabi M, Salehi M, Mali S, Akbari Oryani M (2016) Effectiveness of coenzyme Q10 in prophylactic treatment of migraine headache: an open-label, add-on, controlled trial. Acta Neurol Belg 117:103–109CrossRefPubMed
25.
Zurück zum Zitat Slater SK, Nelson TD, Kabbouche MA, LeCates SL, Horn P, Segers A, Manning P, Powers SW, Hershey AD (2011) A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia 31(8):897–905CrossRefPubMed Slater SK, Nelson TD, Kabbouche MA, LeCates SL, Horn P, Segers A, Manning P, Powers SW, Hershey AD (2011) A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia 31(8):897–905CrossRefPubMed
26.
Zurück zum Zitat Cady RK, Goldstein J, Nett R, Mitchell R, Beach ME, Browning R (2011) A double-blind placebo-controlled pilot study of sublingual feverfew and ginger (LipiGesic™ M) in the treatment of migraine. Headache 51(7):1078–1086CrossRefPubMed Cady RK, Goldstein J, Nett R, Mitchell R, Beach ME, Browning R (2011) A double-blind placebo-controlled pilot study of sublingual feverfew and ginger (LipiGesic™ M) in the treatment of migraine. Headache 51(7):1078–1086CrossRefPubMed
27.
Zurück zum Zitat D’Andrea G, Bussone G, Allais G, Aguggia M, D’Onofrio F, Maggio M, Moschiano F, Saracco MG, Terzi MG, Petretta V, Benedetto C (2009) Efficacy of Ginkgolide B in the prophylaxis of migraine with aura. Neurol Sci 1:S121–S124CrossRef D’Andrea G, Bussone G, Allais G, Aguggia M, D’Onofrio F, Maggio M, Moschiano F, Saracco MG, Terzi MG, Petretta V, Benedetto C (2009) Efficacy of Ginkgolide B in the prophylaxis of migraine with aura. Neurol Sci 1:S121–S124CrossRef
28.
Zurück zum Zitat Orr SL, Friedman BW, Christie S, Minen MT, Bamford C, Kelley NE, Tepper D (2016) Management of adults with acute migraine in the emergency department: the American Headache Society evidence assessment of parenteral pharmacotherapies. Headache 56(6):911–940CrossRefPubMed Orr SL, Friedman BW, Christie S, Minen MT, Bamford C, Kelley NE, Tepper D (2016) Management of adults with acute migraine in the emergency department: the American Headache Society evidence assessment of parenteral pharmacotherapies. Headache 56(6):911–940CrossRefPubMed
Metadaten
Titel
Usefulness of nutraceuticals in migraine prophylaxis
verfasst von
Florindo D’Onofrio
Simona Raimo
Daniele Spitaleri
Gerardo Casucci
Gennaro Bussone
Publikationsdatum
01.05.2017
Verlag
Springer Milan
Erschienen in
Neurological Sciences / Ausgabe Sonderheft 1/2017
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-017-2901-1

Weitere Artikel der Sonderheft 1/2017

Neurological Sciences 1/2017 Zur Ausgabe

CLINICAL ASPECTS OF HEADACHE

Vestibular migraine: who is the patient?

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.